Fremanezumab data in The Lancet demonstrate clinically meaningful reduction in migraines
Teva announced that results from the Phase IIIb FOCUS study, which examined fremanezumab versus placebo in adult migraine patients who previously experienced inadequate responses to two to four classes of preventive treatments, were published online ahead of print in The Lancet. August 21, 2019